XM无法为美国居民提供服务。
G
G

GSK


市场新闻

UK Stocks-Factors to watch on Oct. 16

UPDATE 1-UK Stocks-Factors to watch on Oct. 16 Adds news items Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening h igher on Wednesday, with futures FFIc1 u p 0 .4%. * ANTOFAGASTA: Antofagasta ANTO.L reported a 15% rise in third-quarter copper output compared to the second quarter, due to destocking of inventories at its Los Pelambres mine and better grades at its Centinela mine in Chile.
A
G
W

UK Stocks-Factors to watch on Oct 16

UK Stocks-Factors to watch on Oct 16 Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.09%. * GSK: British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia.
B
G
W
U

GSK sues Moderna for US patent infringement over COVID, RSV vaccines

UPDATE 2-GSK sues Moderna for US patent infringement over COVID, RSV vaccines Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna Adds information about RSV vaccine claims in paragraphs 1 and 6 By Blake Brittain Oct 15 (Reuters) - British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S.
G
N
P

GSK Says Both Anchor Trials Of Depemokimab Met Their Co-Primary Endpoints

BRIEF-GSK Says Both Anchor Trials Of Depemokimab Met Their Co-Primary Endpoints Oct 14 (Reuters) - GSK plc GSK.L : GSK PLC - POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB GSK PLC - PRIMARY ENDPOINTS MET WITH SIGNIFICANT REDUCTION IN NASAL POLYP SIZE GSK PLC - POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB GSK PLC - SIMILAR INCIDENCE AND SEVERI
G

UK stocks slip as some companies trade ex-dividend; GSK shines

UPDATE 1-UK stocks slip as some companies trade ex-dividend; GSK shines For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window GSK rises after settlement of 80,000 Zantac litigations Precious metal miners jump on gold surge FTSE 100 down 0.1%, FTSE 250 off 0.6% Updated at 1550 GMT By Shubham Batra and Khushi Singh Oct 10 (Reuters) - The UK's main stock indexes slipped on Thursday as some of the companies traded without the entitlement of their
A
E
G
K
T
N
T
U

Sanofi sale is critical health check for mega LBOs

BREAKINGVIEWS-Sanofi sale is critical health check for mega LBOs The author is a Reuters Breakingviews columnist. The opinions expressed are her own. By Aimee Donnellan LONDON, Oct 10 (Reuters Breakingviews) - Sanofi SASY.PA is about to deliver a critical health check to the buyout world. The $140 billion French pharmaceutical group is in talks with rival bidders Clayton Dubilier & Rice and PAI Partners to sell its consumer drugs unit for 15 billion euros, per Bloomberg reports.
G
G
S

Oil prices could reach $90/bbl if Middle East conflict hits supplies

LIVE MARKETS-Oil prices could reach $90/bbl if Middle East conflict hits supplies STOXX 600 down 0.2% Healthcare leads, tech lags GSK jumps on Zantac settlement Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com OIL PRICES COULD REACH $90/BBL IF MIDDLE EAST CONFLICT HITS SUPPLIES A supply disruption from escalating tensions in the Middle East could see oil pric
G
B
E
F
U
G

European shares mostly lower; markets await US CPI

LIVE MARKETS-European shares mostly lower; markets await US CPI STOXX 600 down 0.2% Healthcare leads, tech lags GSK jumps on Zantac settlement Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN SHARES MOSTLY LOWER; MARKETS AWAIT US CPI Major European bourses nudged lower on Thursday as markets awaited U.S.
G
B
E
F
U
G

GSK rises after settlement of 80,000 Zantac litigations

BUZZ-GSK rises after settlement of 80,000 Zantac litigations ** Shares of British drugmaker GSK GSK.L gains 5.4% to 1,536p - top gainer on FTSE 100 .FTSE index ** Shares on track for the best one-day pct gain since Dec. 2022 ** Settled about 80,000 or 93% of Zantac litigations for up to $2.2 bln ** Analysts had estimated costs as high as $3.5 bln *
G
U

GSK shares jump on $2.2 billion Zantac settlement

UPDATE 3-GSK shares jump on $2.2 billion Zantac settlement Settlement resolves 80,000 or 93% of pending US cases GSK top gainer on FTSE-100, best one-day gain since Dec 2022 To record 1.8 billion pounds charge in Q3 results Rewrites paragraphs 1-3, adds investor comment in 4-5 By Maggie Fick and Yamini Kalia Oct 10 (Reuters) - GSK GSK.L shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S.
G
J
P
S
U

New York Times business news - Oct 10

PRESS DIGEST- New York Times business news - Oct 10 Oct 10 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy. - British drugmaker GSK GSK.L said it would pay up to $2.2 billion to settle most lawsuits filed against it in the U.S. that claimed a discontinued version of its heartburn drug Zantac caused cancer.
G

UK Stocks-Factors to watch on Oct 10

UPDATE 1-UK Stocks-Factors to watch on Oct 10 Adds new items, updates futures Oct 10 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Thursday, with futures FFIc1 up 0.2%. * TRITAX EUROBOX: Brookfield Asset Management BAM.TO has agreed to buy Tritax EuroBox EBOX.L for 1.1 billion pounds ($1.44 billion), including debt, kicking off a possible takeover battle for the European logistics real estate firm.
G
H
K
T
W
T

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits

GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits Oct 10 (Reuters) - Shares of GSK GSK.L are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn drug Zantac caused cancer. The agreement, announced on Wednesday, resolved 80,000 or 93% of the pending cases against the company in the U.S.
G
J

British Business - Oct 10

PRESS DIGEST-British Business - Oct 10 Oct 10 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy. The Times - British paper and packaging firm Mondi MNDI.L has agreed to buy the German, Benelux and UK packaging assets of Schumacher Packaging for 634 million euros ($693.79 million) including debt, to expand in Western Europe.
G
M

UK Stocks-Factors to watch on Oct 10

UK Stocks-Factors to watch on Oct 10 Oct 10 - Britain's FTSE 100 .FTSE index is seen opening higher, with futures FFIc1 up 0.29%. * GSK: GSK GSK.L has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on Wednesday. * METALS: Copper prices rose in London on Thursday, rebounding from a two-week low hit in the previous session, as traders and investors awaited a China b
G
K
T
W
T

Financial Times - Oct 10

PRESS DIGEST- Financial Times - Oct 10 Oct 10 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - HSBC targets senior bankers in cost-cutting plan - UK ministers fire starting gun on landmark worker rights reform - GSK reaches $2.2 bln Zantac settlement in US - Bernard Arnault partners with Red Bull to buy Paris FC in latest move into sport Overview - HSBC HSBA.L CEO Georges Elhedery plans
G
H
L

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln

UPDATE 2-GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 bln GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing New throughout, adds detail on litigation, statements from plaintiffs and GSK By Brendan Pierson Oct 9 (Reuters) - GSK GSK.L has agreed to pay up to $2.2 billion to settle most lawsuits in U.S.
G
P
S

GSK reaches up to $2.2 billion settlement in Zantac US state court cases

GSK reaches up to $2.2 billion settlement in Zantac US state court cases Oct 9 (Reuters) - GSK GSK.L said on Wednesday it had reached agreements with ten plaintiff firms, representing 93% of U.S. state court Zantac product liability cases pending against the drugmaker, for up to $2.2 billion. Reporting by Aatrayee Chatterjee in Bengaluru
G

GSK Says Company To Resolve 93% Of U.S. Zantac Cases For Up To $2.2 Billion

BRIEF-GSK Says Company To Resolve 93% Of U.S. Zantac Cases For Up To $2.2 Billion Oct 9 (Reuters) - GSK plc GSK.L : GSK PLC - ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS GSK PLC - TO RESOLVE 93% OF U.S. ZANTAC CASES FOR UP TO $2.2 BILLION GSK PLC - SETTLES QUI TAM COMPLAINT FOR $70 MILLION GSK PLC - TO RECOGNISE £1.8 BILLION CHARGE IN Q3 RESULTS FO
G

GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up

ANALYSIS-GSK, Pfizer RSV vaccine sales fall in US as millions fewer people line up Regulators narrowed the targeted age group for RSV vaccines Demand for RSV vaccines has fallen by up to two-thirds GSK maintains market lead despite reduced sales By Michael Erman Oct 8 (Reuters) - U.S. sales of RSV vaccines from GSK GSK.L and Pfizer PFE.N are down significantly after regulators narrowed the targeted age group and said it was a once-in-a-lifetime shot for now, excluding millions of people who got
G
P
W



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明